Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis - Takeaways - MDSpire

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

  • By

  • Xiaofan Liao

  • Xian Huang

  • Guilan Yang

  • Xia Wang

  • Qifeng Li

  • Yuan Lu

  • May 8, 2026

  • 0 min

Share

  • 1

    Primary cutaneous amyloidosis (PCA) is a chronic skin disorder characterized by intense itching and amyloid accumulation in the dermis.

  • 2

    Ivarmacitinib, a selective JAK1 inhibitor, has shown promise in treating refractory PCA by targeting inflammatory pathways.

  • 3

    A 65-year-old male with severe, treatment-resistant PCA experienced significant improvement after starting ivarmacitinib.

  • 4

    The patient reported a complete resolution of pruritus within one week of initiating ivarmacitinib treatment.

  • 5

    This case suggests that ivarmacitinib may be an effective and well-tolerated option for patients with refractory PCA.

Original Source(s)

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

  • by Xiaofan Liao, Xian Huang, Guilan Yang, Xia Wang, Qifeng Li, Yuan Lu

  • May 8, 2026

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

Topical Postbiotics Show Promise for Acne, Eczema

Postbiotics linked to improvements in acne and eczema, with limited data in rosacea